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ORIGINAL STUDYHerpes Simplex Virus Type 2 Seroprevalence Among
DifferentNational Populations ofMiddle East andNorth
African Men
Soha R. Dargham, MPH,* Gheyath K. Nasrallah, PhD,†‡ Enas S. Al-Absi, BSc,‡
Layla I. Mohammed, BSc,‡ Rana S. Al-Disi, BSc,†
Mariam Y. Nofal, BSc,† and Laith J. Abu-Raddad, PhD*§Background: There are limited data on herpes simplex virus type 2
(HSV-2) seroprevalence in the Middle East and North Africa (MENA).
We examined country- and age-specific HSV-2 seroprevalence among se-
lect MENA populations residing in Qatar.
Methods: Sera were collected from male blood donors attending Hamad
Medical Corporation between June 2013 and June 2016. Specimens were
screened for anti-HSV-2 IgG antibodies following a 2-test algorithm:
HerpeSelect 2 ELISA was used to identify HSV-2–positive specimens,
and Euroline-WB was used to confirm positive and equivocal specimens
for final HSV-2 status. Trends and associations with HSV-2 seropositivity
were assessed.
Results: Of the 2077 tested sera, 61 were found and confirmed positive.
The proportion of those confirmed positive increased steadily with
HerpeSelect 2 ELISA index value, ranging from 16.3% for index values
of 1.101 to 1.999 to 92.9% for index values of 4 or greater. Nationality-
specific seroprevalence was 6.0% (95% confidence interval [CI], 4.1%–
8.8%) in Qataris, 5.3% (95% CI, 2.5%–11.1%) in Iranians, 4.2% (95%
CI, 1.8%–9.5%) in Lebanese, 3.1% (95% CI, 1.2%–7.7%) in Sudanese,
3.0% (95% CI, 1.4%–6.4%) in Palestinians, 2.2% (95% CI, 1.1%–4.3%)
in Egyptians, 2.0% (95% CI, 1.0%–5.0%) in Syrians, 1.0% (95% CI,
0.3%–3.6%) in Jordanians, 0.7% (95% CI, 0.1%–3.7%) in Yemenis, and
0.5% (95% CI, 0.1%–2.8%) in Pakistanis. There was evidence for higher
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482 SexConclusions: The seroprevalence of HSV-2 was in the range of few per-
centage points. There were no major differences in seroprevalence by nation-
ality. These findings add to our understanding of HSV-2 epidemiology in
MENA and indicate unmet needs for sexual health and control of sexually
transmitted infections.
Herpes simplex virus type 2 (HSV-2) is a lifelong infection anda prevalent sexually transmitted infection (STI).1,2 It was
estimated that, for 2012, there were more than 400 million
prevalent HSV-2 infections worldwide with an annual inci-
dence of nearly 20 million infections.3 Herpes simplex virus
type 2 is a cause of a range of diseases,4 most notably genital
ulcer disease, where HSV-2 is a leading, if not the leading,
cause of genital ulcer disease in developed and developing
countries.4,5 Evidence suggests an epidemiologic synergy be-
tween HSV-2 infection and HIV infection.6,7
An intriguing aspect of HSV-2 epidemiology is that HSV-2
antibody prevalence (seroprevalence) could be used as a “summary
collective measure” of sexual risk behavior and HIV epidemic po-
tential.8 A recent mathematical modeling study demonstrated that
HSV-2 seroprevalence in a population is a reflection of key statistics
of sexual network structure.9 The mean and variance of the number
of sexual partners, as well as concurrency and clustering coefficient,
were the strongest predictors of HSV-2 seroprevalence.9 A system-
atic review and meta-analyses of global HSV-2 and HIV data,10 andG.K.N. acknowledges support by Qatar University internal grant
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HSV-2 Seroprevalence in MENAmathematical modeling9 identified a strong and statistically signifi-
cant association, with a Spearman rank correlation of approximately
0.7, between HSV-2 seroprevalence and HIV seroprevalence across
populations. These findings highlight how HSV-2 seroprevalence
can identify populations and/or sexual networks at risk for future
HIVexpansion.
Despite the growth in STI research in the Middle East and
North Africa (MENA) recently,11,12 our knowledge of HSV-2
epidemiology remains limited. A systematic review of HSV-2
seroprevalence data in MENA identified only a small number
of studies.8 Most studies used also diagnostic tests of question-
able validity and with cross-reactivity with the highly prevalent
HSV-1 antibodies.8,13 With only few acceptable-quality studies
in MENA, we aimed in the present study to provide measures of
the nationality-specific and age-specific HSV-2 seroprevalence
in select MENA populations residing in Qatar. This is the first
time that HSV-2 seroprevalence measures are reported for several
nationalities. We used a 2-test algorithm to screen specimens for
HSV-2 antibodies, to avoid key limitations in existing literature.8
Qatar is a MENA country with a resident population of
2.2 million in 2014, of which only 12% are Qataris.14 Qatar provided
an opportune setting for our study, asmost of the population are short-
term expatriate residents.14 These expatriates came to Qatar in recent
years for contractual employment with the rapid economic expan-
sion.14With a fraction of these expatriates beingMENA expatriates14
and with the existing availability of a sample of specimens from
male blood donors,15–18 we aimed to assess HSV-2 seroprevalence
in male blood donors from 10 MENA nationalities.
MATERIALS AND METHODS
Study Design and Participants
This was an opportunistic cross-sectional study on volun-
teer male blood donors attending the donation center at Hamad
Medical Corporation, the primary provider of health care in
Qatar, between June 2013 and June 2016. Blood donation in
Qatar is a common and accessible practice, and individuals from
diverse socioeconomic strata participate in donation campaigns.
A total of 5973 anonymized blood sera specimens were originally
obtained for other studies.15–18 All specimens were anonymously
collected and unidentified at the donation center and subsequently
provided to study investigators for testing.
Collected basic demographic data included only national-
ity, age, and sex. A total of 4525 specimens satisfied the eligibility
criteria (male sex and MENA nationals residing in Qatar) and
served as the original sampling cohort. There were too few spec-
imens (only 88) to extend the study to female residents. The
anonymized specimen collection was approved by Hamad Med-
ical Corporation ethics board, and this study was also approved
by the ethics boards and research committees at Qatar University
and Weill Cornell Medicine—Qatar.
We powered final sample sizes of the study for 5% signifi-
cance level. To estimate a 2% age-specific HSV-2 seroprevalence
with a 4% precision level, we calculated a sample size of 50 for
each 5-year age group in each nationality. To estimate a 2%
nationality-specific HSV-2 seroprevalence with a 2% precision
level, we calculated a sample size of 200 for each nationality. We
based the 2% seroprevalence on observed seroprevalence in
Saudi Arabia,19 a neighboring country.
We used a similar sampling strategy to that of a previous
study on HSV-1 seroprevalence.13 We selected a random sample
of 50 subjects per age group for estimating the age-specific
HSV-2 seroprevalence for each of Egypt, the Fertile Crescent
(merged sample for Iraq, Jordan, Lebanon, Palestine, and Syria),Sexually Transmitted Diseases • Volume 45, Number 7, July 2018and Qatar. The neighboring countries of Iraq, Jordan, Lebanon,
Palestine, and Syria were merged into one sample “Fertile Cres-
cent” because of insufficient sample size for any country individ-
ually, and because of socioeconomic and sociocultural similarity.
For estimating the nationality-specific seroprevalence, we selected
a random sample of 200 subjects for each of Jordan, Pakistan,
Palestine, and Syria, whereas all available specimens (<200)
for Iran, Lebanon, Sudan, and Yemen were included.
Biological Specimen Laboratory Analysis
In light of known limitations and recommendations in
conducting HSV-2 serology,20–22 we used a 2-test algorithm for
identifying positive specimens, using 2 of the most commonly
used commercial assays.23,24 The first stage included screening
for the presence of anti-HSV-2 IgG antibodies using an enzyme-
linked immunosorbent assay (ELISA), and the second stage in-
cluded confirmation of HSV-2 IgG seropositivity using a Western
blot (WB) assay for both positive and equivocal specimens.
For screening, we aliquoted 50 μL of sera from existing sera
specimens and tested for the presence of anti–HSV-2 IgG using
HerpeSelect 2 ELISA kits (Cat. No. EL0910G-5; Focus Diagnos-
tics, Cypress, CA).25 This kit was approved for laboratory diagno-
sis of anti–HSV-2 IgG by the US Food andDrugAdministration.25
We interpreted the analysis and results according to the manufac-
turer's instructions: sera with optical density index values (cutoff )
less than 0.90 were considered negative, values greater than 1.10
were considered positive, and values ranging between 0.90 and
1.10 were considered equivocal.25 Equivocal specimens were
retested by using HerpeSelect 2 ELISA kits for final ELISA re-
sults, and if remained equivocal, they were considered equivocal
by ELISA testing.
For confirmation of seropositivity, we retested all positive
and equivocal specimens for the presence of anti–HSV-2 IgG
using Euroline-WB assays (Cat. No. DY 2531-2401-1G; Euroimmun
Laboratory, Luebeck, Germany).26 Analysis and results were
interpreted according to the manufacturer's instructions.
The final results for the equivocal specimens by Euroline-WB
and for the specimens with no sufficient serum for Euroline-WB
confirmatory testing were determined, as informed by previous
work,20,21 based on the HerpeSelect 2 ELISA index value (posi-
tive if index value ≥3 and negative if index value <3).
Data Analysis
We analyzed the data using SPSS version 24. We catego-
rized age into 8 brackets: ≤24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, and≥55 years. To assess the age-specific seroprev-
alence of the study population for Egypt, Fertile Crescent, and
Qatar, we cross-tabulated age and HSV-2 serostatus. We assessed
trends using the Cochran-Armitage test. To estimate crude and ad-
justed associations of age and nationality with HSV-2 serostatus,
we conducted logistic regression to determine the odds ratios.
RESULTS
We tested a total of 2077 specimens for HSV-2 IgG antibod-
ies using HerpeSelect 2 ELISA kits. The median age was 37 years.
HerpeSelect 2 ELISA testing identified 1955 sera as negative, 116
as positive, and 6 as equivocal (Fig. 1). We performed confirmatory
testing for HSV-2 antibodies using Euroline-WB assays for 117
specimens. Fifty-eight specimens were confirmed positive for
HSV-2 antibodies and 3 were equivocal.
There was not enough serum for confirmatory testing for 5
specimens identified as positive using HerpeSelect 2 ELISA
(Fig. 1). Final results for these specimens, as well as for the 3
equivocal specimens by Euroline-WB, were determined based483
Figure 1. Overview of the serological testing for anti-HSV-2 IgG
antibodies in its 2 stages of screening and confirmation.
Dargham et al.on the HerpeSelect 2 ELISA index value (positive if index value
≥3 and negative if index value <3). The final results for these 8
specimens were 5 negative and 3 positive. Accordingly, final re-
sults of the serology testing for the 2077 specimens identified 61
sera as positive and 2016 as negative.
Figure 2 shows the proportion of HSV-2 HerpeSelect 2
ELISA positive results confirmed positive by Euroline-WB as-
says, by index value. Of the 117 HerpeSelect 2 ELISA (111 posi-
tive and 6 equivocal) specimens retested (Fig. 1), 49.6% were
confirmed positive by Euroline-WB (Fig. 2). The proportion of
specimens confirmed positive increased steadily with index value
and ranged from a low of 16.3% for index value of 1.101 to 1.999
to a high of 92.9% for index value of 4 or greater. The trend of higher
positive concordance with higher index value was statisticallyFigure 2. Proportion of HSV-2 HerpeSelect 2 ELISA positive results confirm
484 Sexsignificant (P value for trend < 0.001). Of the 6 equivocal speci-
mens, 5 were confirmed negative by Euroline-WB assays and 1
remained equivocal.
We estimated the nationality-specific HSV-2 seroprevalence
for 10 populations (Fig. 3A and Table S1 of Supplementary
Content, http://links.lww.com/OLQ/A234). Seroprevalence ranged
between 0.5% (95% confidence interval [CI], 0.1%–2.8%) for
Pakistanis and 6.0% (95% CI, 4.1%–8.8%) for Qataris.
Seroprevalence was 5.3% (95% CI, 2.5%–11.1%) in Iranians,
4.2% (95% CI, 1.8%–9.5%) in Lebanese, 3.1% (95% CI, 1.2%–
7.7%) in Sudanese, 3.0% (95% CI, 1.4%–6.4%) in Palestinians,
2.2% (95% CI, 1.1%–4.3%) in Egyptians, 2.0% (95% CI,
1.0%–5.0%) in Syrians, 1.0% (95% CI, 0.3%–3.6%) in
Jordanians, and 0.7% (95% CI, 0.1%–3.7%) in Yemenis.
Table 1 and Figure 3B show the estimated age-specific
HSV-2 seroprevalence for Egyptians, Fertile Crescent nationals,
and Qataris. Seroprevalence tended to grow with age, but the trend
was statistically significant only forQataris (Pvalue for trend=0.010).
Highest seroprevalence was in the older age groups.
There were only few significant associations between age
or nationality and HSV-2 infection in univariable analyses
(Table S2 of Supplementary Content, http://links.lww.com/OLQ/
A234). For example, compared with participants 24 years or
younger, the crude odd ratios (ORs) for seropositivity were sig-
nificantly higher in those aged 40 to 44 years (OR, 4.93; 95%
CI, 1.10–22.06) and in those 55 years or older (OR, 7.97;
95% CI, 1.74–36.45). All associations remained significant in
the multivariable analysis.
DISCUSSION
This is, to our knowledge, the largest study of HSV-2 sero-
prevalence in MENA. We reported the nationality-specific and
age-specific seroprevalence for several national populations for
the first time in the literature, and we used a 2-test algorithm using
quality testing kits and confirmatory testing to avoid limitations in
existing studies.8 We found that HSV-2 seroprevalence is in the
range of few percentage points—on the low side compared with
global levels.1,2,8,27 By world region, seroprevalence seems
broadly in the range of 10% to 30% in Asia, 5% to 25% in
Europe, 20% to 40% in Latin America, 15% to 25% in North
America, and 10% to 70% in sub-Saharan Africa.1,2,8,27
The seroprevalence of HSV-2 tended to grow with age, as
expected reflecting cumulative risk of exposure.1 Although thereed positive by the Euroline-WB assay, by optical density index value.
ually Transmitted Diseases • Volume 45, Number 7, July 2018
Figure 3. Estimates of HSV-2 nationality-specific (A) and age-specific (B) seroprevalence amongmale blood donors currently residing in Qatar,
but from different MENA countries.
HSV-2 Seroprevalence in MENAwas some evidence for variation in seroprevalence by nationality,
seroprevalence was overall similar. This is to be contrasted with
HSV-1, which showed large variations in seroprevalence, by age
and nationality, in this very same blood donor sample.13
Observed HSV-2 seroprevalence was comparable to that
found in other MENA general population studies that used
reasonable-quality diagnostics.8,19 Seroprevalence, however, was
substantially less than that found in studies that used poor-
quality diagnostics known for cross-reactivity with the highly
prevalent HSV-1 antibodies.8 This affirms the need to insure use
of quality type-specific diagnostics, to avoid generating clinically
or epidemiologically noninterpretable, or even misleading results.
Only half of the HerpeSelect 2 ELISA positive results were
confirmed positive by Euroline-WB. The proportion of those con-
firmed positive increased steadily with index value and was
greater than 50% only for index values of greater than 3. These
findings concur with earlier studies that used HerpeSelect 2
ELISA.20,21 Given the variation in test performance by popula-
tion,21,22 our study provides useful data for the performance of this
commonly used assay in MENA populations. They also testify to
the importance of a 2-test algorithm,21 or the use of a different cut-
off index value in interpreting results.21
Because HSV-2 seroprevalence can be seen as a proxy
“biomarker” of sexual risk behavior in a population,9 our results
suggest a lower risk behavior than that in most other regions.
This finding is supported by studies of self-reported sexual be-
havior,27,28 notwithstanding the many limitations of such self-
reported data.8 Importantly, this finding is supported by the
generally lower levels of other STIs in MENA.27,28 Despite this,
our study demonstrates that there are sexual networks where
STIs are propagating. There is also likely an HSV-2 disease bur-
den that needs to be addressed in a context of limited programs
for sexual health and STIs.
There was overall a weak association between HSV-2 sero-
prevalence and age. This pattern remains to be explained, but we
speculate that this may relate to statistical power with the small
number of positives. Alternatively, the force of infection may beSexually Transmitted Diseases • Volume 45, Number 7, July 2018low in MENA resulting in a small prevalence and a more diffused
seroprevalence age distribution.29 Another explanation is that suc-
cessive birth cohorts may have had a variable experience in being
exposed to HSV-2 in different eras, possibly because of variation
in risk behavior over time.27
This study has limitations. The sample consisted of male
blood donors with no population-based and probability-based
sampling. Depending on the main outcome, nationality- versus
age-specific seroprevalence, different sample selection methodol-
ogies were used, which may affect estimated seroprevalence. Al-
though blood donation is a common practice in Qatar, blood
donors are more likely to be a healthy population with possibly
lower levels of sexual risk behavior and STIs. The seroprevalence
HSV-2 is often 2-fold higher among women than among
men,1–3,30 but our sample was exclusively from men. These con-
siderations suggest that our estimated seroprevalence is possibly
underestimating actual HSV-2 seroprevalence in the population
at large.
Because all recruited individuals were residing in Qatar, we
cannot be certain as to how representative these individuals are of
citizens in their home countries. However, expatriates in Qatar are
not permanent immigrants, most often stay for few years, and are
predominantly recent residents. Because they have spent most of
their lifetime in their home countries, their seroprevalence is prob-
ably representative of the exposure risk in their home countries,
rather than in Qatar.
Very basic sociodemographic variables were collected,
restricting our ability to assess relevant individual-level associa-
tions such as with sexual behavior. Collecting sexual behavior data
is challenging in the MENA context—supporting the value of
using HSV-2 (among other STIs) as proxy biomarkers of sexual
risk behavior.8,9
Because of logistical considerations (regulations of ship-
ping specimens and cost of conducting the University of
Washington [UW] WB), we did not use the criterion standard
UW-WB assay for serology testing. However, to minimize issues
with diagnosis, we used a 2-test algorithm for identifying positive485
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486 Sexspecimens, using 2 of the most commonly used commercial as-
says, including aWB assay that resembles the UW-WB assay.23,24
Moreover, used assays used different biological formats, and their
performance has already been investigated independently with
reference to UW-WB.20–24 Having said so, with the relative pau-
city of data on the Euroline-WB assay, it is of value to examine
further the performance of this assay relative to the UW-WB.
In conclusion, this study fills a gap in HSV-2 regional and
nationality-specific seroprevalence data. Seroprevalence in men
was in the range of few percentage points—on the low side of
the global range. Seroprevalence increased with age, but no major
differences by nationality were identified. Performance of
HerpeSelect 2 ELISA in MENA populations demonstrated simi-
larities to its performance elsewhere, stressing the need for careful
interpretation of the results by index value and the utility of a
2-test algorithm for diagnosis. These findings add to our under-
standing of STI epidemiology and sexual behavior inMENA. De-
spite the rather low HSV-2 seroprevalence, they also highlight the
need for programs to tackle STIs and address broader sexual
health needs.
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